A few months after emerging from stealth, Praxis is handed a clinical hold for lead depression drug
Less than a month after Praxis Precision Medicines hit Wall Street with an upsized IPO, the FDA has slapped a clinical hold on its lead candidate for major depressive disorder (MDD), sending shares spiraling.
Without providing much information, the FDA said in an email that it reviewed Praxis’ IND for its Phase II/III trial, and is placing a full clinical hold on the study. More details should come in the next 30 days, according to the email. Praxis says it has reached out to the agency, which said it isn’t done finalizing comments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
